Related Experiment Video
Updated: Jan 6, 2026
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications
George Kontogeorgos1,2, Eleni Thodou3, Mary Koutourousiou4
1First Propaepeudic Department of Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens, 75 Mikras Asias Str., 11527, Athens, Attica, Greece. gkonto@med.uoa.gr.
Introduction:
Temozolomide (TMZ) is currently considered as a rational therapeutic option for patients with progressively aggressive pituitary adenomas and carcinomas not responding to conventional therapies. Administration of TMZ results in clinical response and improvement in survival of many of these patients depending upon the expression of the DNA repair enzyme O-6 methylguanine DNA transferase (MGMT). Low or negative MGMT immunoreactivity predicts responsiveness to TMZ therapy. Therefore, MGMT serves as a criterion to select candidate patients anticipating response to treatment.
Materials And Methods:
The MGMT expression was investigated in 25 pituitary adenomas with Ki-67 labeling index more that 3% and p53 expression, using various antigen retrieval protocols. After direct application of the antibody, only one adenoma yielded positive for MGMT. However, after pretreatment of tissue sections with antigen retrieval protocols, another 3 adenomas, initially negative turned to positive.
Conclusions:
These findings could explain lack of response to TMZ treatment in patients with false negative MGMT immunohistochemistry. Evaluation of tumor samples for MGMT expression should carefully be carried-out using the optimum immunohistochemical protocol to obtain consistent and reliable results that help to identify patients that could respond to TMZ therapy.
Insights
Optimizing immunohistochemistry for O-6 methylguanine DNA transferase (MGMT) is crucial. Proper protocols ensure accurate MGMT expression analysis, identifying patients likely to respond to temozolomide (TMZ) therapy for aggressive pituitary tumors.
Area of Science:
- Oncology
- Neuroendocrinology
- Molecular Biology
Background:
- Temozolomide (TMZ) is a potential treatment for aggressive pituitary adenomas and carcinomas.
- Patient response to TMZ therapy correlates with the expression of O-6 methylguanine DNA transferase (MGMT).
- Low or negative MGMT expression predicts responsiveness to TMZ, making it a key selection criterion.
Purpose of the Study:
- To investigate the impact of immunohistochemical protocols on MGMT expression analysis in pituitary adenomas.
- To determine the optimal method for accurately assessing MGMT levels for predicting TMZ response.
Main Methods:
- MGMT expression was evaluated in 25 pituitary adenomas with high Ki-67 and p53 expression.
- Various antigen retrieval protocols were applied to tissue sections.
- Immunohistochemistry was performed to detect MGMT expression.
Main Results:
- Direct antibody application yielded positive MGMT in only one adenoma.
- Pretreatment with antigen retrieval protocols converted 3 initially negative adenomas to positive.
- This highlights variability in MGMT detection based on protocol.
Conclusions:
- Inconsistent MGMT detection can lead to false negatives, explaining lack of response to TMZ.
- Careful selection of immunohistochemical protocols is essential for reliable MGMT assessment.
- Accurate MGMT evaluation is critical for identifying suitable candidates for temozolomide therapy.
